Mahmood Mohamadi, MD
Endocrinology, Diabetes & Metabolism · Oxon Hill, MDNPI 1700828233
Payments from drug & device makers
Across 208 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$444
- Merck$318
- Novo Nordisk$216
- Sanofi-aventis U.S. LLC$197
- Antares Pharma, Inc.$152
- plus $640 from 19 others
What the payments were for
- Food & beverage$3,72599%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 85 | $1,778 |
| AstraZeneca | 24 | $444 |
| Merck | 32 | $318 |
| Novo Nordisk | 12 | $216 |
| Sanofi-aventis U.S. LLC | 11 | $197 |
| Antares Pharma, Inc. | 8 | $152 |
| AbbVie | 3 | $65 |
| Clarus Therapeutics Inc. | 5 | $62 |
| Boehringer Ingelheim | 4 | $62 |
| Acerus Pharmaceuticals Corporation | 3 | $62 |
| Pfizer | 3 | $58 |
| Medtronic(2 entities) | 3 | $54 |
| Johnson & Johnson | 2 | $43 |
| Amarin Pharma, Inc. | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Mannkind Corporation | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $13 |
| Abbott | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$3,746 in reported general payments places this provider in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $116,527 |
| TrulicityDulaglutide | 64 | $107,712 |
| MounjaroTirzepatide | 78 | $107,285 |
| FarxigaDapagliflozin Propanediol | 74 | $70,447 |
| OzempicSemaglutide | 44 | $70,157 |
| JanumetSitagliptin Phos/Metformin Hcl | 53 | $59,652 |
| JanuviaSitagliptin Phosphate | 40 | $49,669 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 34 | $42,194 |
| EliquisApixaban | 27 | $30,893 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,364 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 46 | $7,615 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $6,686 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 19 | $4,179 |
| Levothyroxine Sodium | 228 | $3,339 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $3,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,778 | $214,997142 claims |
| MerckJanumet, Januvia, Janumet Xr | $318 | $151,516127 claims |
| Boehringer IngelheimJardiance | $62 | $116,52778 claims |
| AstraZenecaFarxiga | $444 | $70,44774 claims |
| Novo NordiskOzempic | $216 | $70,15744 claims |
| PfizerEliquis | $58 | $30,89327 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $3,339228 claims |
| AbbVieSynthroid | $65 | $1,66235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Oxon Hill
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.